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Abstract
The paucity of randomized breast cancer trials in elderly patients limits the data available for optimal treatment
selection in this patient population, especially in elderly patients with comorbidities and increased suscepti-
bility to adverse events. In the BOLERO-2 (Breast Cancer Trials of Oral Everolimus-2) phase III trial (N [ 724)
everolimus (EVE) plus exemestane (EXE) provided substantial clinical beneﬁt in elderly patients with hormone
receptorepositive (HRD) advanced breast cancer and was generally well tolerated.
Background: Postmenopausal women with hormone receptorepositive (HRþ) breast cancer in whom disease pro-
gresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with
exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 trial demonstrated that adding
everolimus (EVE) to EXE improved progression-free survival (PFS) while maintaining quality of life when compared with
EXE alone. Because many women with HRþ advanced breast cancer are elderly, the tolerability proﬁle of EVE plus EXE
in this population is of interest. Patients and Methods: BOLERO-2, a phase III randomized trial, compared EVE
(10 mg/d) and placebo (PBO), both plus EXE (25 mg/d), in 724 postmenopausal women with HRþ advanced breast
cancer recurring/progressing after treatment with NSAIs. Safety and efﬁcacy data in elderly patients are reported at
18-month median follow-up. Results: Baseline disease characteristics and treatment histories among the elderly
subsets ( 65 years, n ¼ 275;  70 years, n ¼ 164) were generally comparable with younger patients. The addition of
EVE to EXE improved PFS regardless of age (hazard ratio, 0.59 [ 65 years] and 0.45 [ 70 years]). Adverse eventsThis work was presented in part at the 48th Annual Meeting of the American Society of
Clinical Oncology; June 1-5, 2012; Chicago, IL.
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422 -(AEs) of special interest (all grades) that occurred more frequently with EVE than with PBO included stomatitis,
infections, rash, pneumonitis, and hyperglycemia. Elderly EVE-treated patients had similar incidences of these AEs as
did younger patients but had more on-treatment deaths. Conclusion: Adding EVE to EXE offers substantially
improved PFS over EXE and was generally well tolerated in elderly patients with HRþ advanced breast cancer. Careful
monitoring and appropriate dose reductions or interruptions for AE management are recommended during treatment
with EVE in this patient population.
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Breast cancer is the most common cancer in women and is a
leading cause of cancer deaths throughout the world.1-3 Moreover,
breast cancer can be considered a disease of aging. Breast cancer
incidence rates in women  65 years of age are nearly 2 to 3 times
greater than in younger women.3 The overall mortality rates from
breast cancer in North America and northern and western Europe
are consistent with incidence patterns in elderly and younger
women.3 Similar incidence and mortality rates are reported for New
Zealand and Australia.3
Aromatase inhibitors (AIs; steroidal or nonsteroidal) are estab-
lished standard of care for postmenopausal patients with hormone
receptorepositive (HRþ) advanced breast cancer.4 However, disease
recurrence or progression while receiving endocrine therapy presents
a substantive challenge in breast cancer. Subsequent treatment
options (eg, other classes of AIs, selective estrogen receptor [ER]
modulators such as tamoxifen or toremifene, or selective ER
downregulators such as fulvestrant) provide limited clinical beneﬁt,
and survival is poor.5 Although chemotherapeutic regimens are
often prescribed after disease progression on an AI,4 it is well
documented that the elderly may be especially vulnerable to cyto-
toxic drug-induced toxicity because of an increased likelihood of
impaired physical, cognitive, and biological functions, as well as the
presence of more comorbidities when compared with younger
patients.6,7 As such, elderly patients are especially at risk for treat-
ment nonadherence,8 thereby elevating the importance of proactive
management of toxicity to maintain treatment adherence.7 Unfor-
tunately, the lack of randomized breast cancer trials in these patients
limits the data available for evidence-based treatment selection and,
coupled with a fear of increased toxicity, may lead to undertreat-
ment of this important and increasing patient population.3,6 Thus,
new treatment approaches are needed for elderly patients with HRþ
breast cancer whose disease has progressed on endocrine therapy and
who may have increased susceptibility to adverse events (AEs).
Activation of the mammalian target of rapamycin (mTOR)
pathway has been associated with elevated ER signaling and breast
cancer progression.9 Alterations in expression levels of phosphati-
dylinositol 3-kinase [PI3K]/mTOR pathway proteins are associated
with poor prognosis in ERþ breast cancer.10 Moreover, both in vitro
and in vivo data indicate that mTOR inhibitors can inhibit cell
proliferation and enhance or restore sensitivity to endocrine thera-
pies (including fulvestrant, letrozole, and tamoxifen).10-14 Ever-
olimus is an orally active once-daily inhibitor of mTOR approved
since 2009 for the treatment of patients with progressive neuroen-
docrine tumors of pancreatic origin, advanced renal cell carcinoma,Clinical Breast Cancer December 2013and subependymal giant-cell astrocytoma associated with tuberous
sclerosis.15 Recently, results from the phase III BOLERO-2 (Breast
Cancer Trials of Oral Everolimus-2) study reported that everolimus
in combination with exemestane (EVE þ EXE) more than doubled
progression-free survival (PFS) when compared with placebo plus
EXE (PBO þ EXE) in postmenopausal patients with advanced
HRþ breast cancer recurring/progressing during or after treatment
with nonsteroidal AIs (NSAIs), which resulted in regulatory
approval of EVE þ EXE for this indication in the United States and
the European Union.16
This report presents the safety and efﬁcacy of EVE þ EXE
compared with PBO þ EXE after a median follow-up of 18 months
in elderly patients included in BOLERO-2.
Patients and Methods
The BOLERO-2 study is an international, multicenter, random-
ized, double-blind, PBO-controlled, phase III trial (ClinicalTrials.
gov registration: NCT00863655). The protocol and results for the
entire study have been reported.16,17 The deﬁnition of the elderly
population as comprising patients  65 years of age is arbitrarily
deﬁned, but the cutoff age of 65 years is considered to be standard for
a number of federal agencies in the United States.18 However,  70
years of age is also relevant for classifying a patient as “elderly,”
because> 30% of breast cancer cases occur in these patients, and this
incidence rate may increase up to the age of 80 years.19,20 Therefore,
the safety and efﬁcacy data for EVEþ EXE vs. PBOþ EXE in elderly
patients (using 65 and 70 years of age as cutoffs), as well as safety data
from patients  75 years of age, are reported here.
Patients
Patients were postmenopausal women with locally advanced or
metastatic, cytologically or histologically conﬁrmed ERþ, human
epidermal growth factor receptor-2 nonampliﬁed (HER2e) breast
cancer not amenable to curative surgery or radiotherapy who had
disease recurrence or progression during or after letrozole or anas-
trozole therapy, as previously described.16
This study was conducted in accordance with the Declaration
of Helsinki, the institutional review board at each participating center,
good clinical practice guidelines, and applicable local regulations. All
patients provided written informed consent before study enrollment.
Study Design
Patients were randomly allocated in a 2:1 ratio to receive on a
daily basis EVE (10 mg) or matching PBO, plus open-label EXE
(25 mg). Randomization was stratiﬁed by the presence of visceral
Table 1 Patient Demographic, Baseline Disease, and Treatment Characteristics
Variable
Patients, %
Age < 70 years Age ‡ 70 years
EVE D EXE
(n [ 364)
PBO D EXE
(n [ 196)
EVE D EXE
(n [ 121)
PBO D EXE
(n [ 43)
Race
White 70.9 74.0 85.1 95.3
Asian 24.2 21.9 8.3 4.7
Black 2.2 1.5 4.1 0
Paciﬁc Islander 0.5 0.5 0 0
Other 2.2 2.0 2.5 0
ECOG Performance Status
0 61.8 61.2 56.2 51.2
1 34.9 34.2 38.8 39.5
2 1.4 1.5 3.3 9.3
Unknown 1.9 3.1 1.7 0
Number of Metastatic Sites
1 32.7 28.6 29.8 18.6
2 30.8 36.2 29.8 30.2
3 21.2 19.9 20.7 30.2
4 10.2 11.2 11.6 18.6
5 3.6 2.6 6.6 2.3
> 5 1.4 1.5 0.8 0
Metastatic Site
CNSa 1.1 0 1.7 0
Viscera 56.6 56.6 63.6 72.1
Lung 29.4 28.6 29.8 53.5
Liver 33.5 31.1 33.1 27.9
Lung and liver 9.3 10.2 8.3 14.0
Bone 79.1 77.0 68.6 79.1
Bone only 23.9 20.9 14.9 11.6
Other 49.2 55.6 54.5 65.1
Previous Chemotherapy
Adjuvant/neoadjuvant only 50.0 43.4 24.8 23.3
Metastases only 13.5 10.2 14.9 7.0
Both adjuvant/neoadjuvant and
metastases
14.6 17.9 4.1 7.0
Previous NSAI Treatment 100 100 100 100
Tamoxifen 51.0 52.6 36.4 37.2
Fulvestrant 15.9 14.3 18.2 25.6
Purpose of NSAI Treatment
Adjuvant/neoadjuvant 30.2 21.9 27.3 32.6
Metastases 64.8 72.4 70.2 60.5
Both adjuvant/neoadjuvant and
metastases
4.9 5.6 2.5 7.0
Sensitive to Hormone Therapy 83.5 84.7 86.8 81.4
Number of Previous Therapiesb
1 10.7 14.8 29.8 32.6
2 28.0 28.1 37.2 34.9
3 29.9 24.5 19.0 18.6
 4 31.3 32.7 14.0 14.0
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Table 1 Continued
Variable
Patients, %
Age < 70 years Age ‡ 70 years
EVE D EXE
(n [ 364)
PBO D EXE
(n [ 196)
EVE D EXE
(n [ 121)
PBO D EXE
(n [ 43)
Key Comorbidities at Study Entry, %
Overall 92.9 93.4 95.0 88.4
Infections and infestations 8.2 7.7 9.1 11.6
Respiratory system abnormalities 17.6 26.0 28.1 25.6
Vascular disorders 41.8 37.8 65.3 65.1
Metabolic and nutritional disorders 35.2 36.2 46.3 39.5
Concomitant Medications, %c (n [ 364) (n [ 195) (n [ 118) (n [ 43)
ACE inhibitors 7.1 7.2 15.3 16.3
Angiotensin II antagonists 5.0 2.6 13.6 11.6
Benzodiazepine derivatives 14.8 13.3 17.0 7.0
Bisphosphonates 48.4 55.9 36.4 51.2
Dihydropyridine derivatives 8.2 6.7 15.3 16.3
HMG-CoA reductase inhibitors 12.4 14.9 18.6 23.3
Natural opium alkaloids 13.5 13.9 18.6 18.6
Platelet aggregation inhibitorsd 9.3 5.1 21.2 30.2
Proton pump inhibitors 14.0 14.9 26.3 20.9
Thyroid hormones 10.2 5.6 12.7 18.6
Abbreviations: ACE ¼ angiotensin-converting enzyme; CNS ¼ central nervous system; ECOG ¼ Eastern Cooperative Oncology Group; EVE ¼ everolimus; EXE ¼ exemestane; HMG-CoA ¼ 3-hydroxy-
3-methylglutaryl coenzyme A; NSAI ¼ nonsteroidal aromatase inhibitor; PBO ¼ placebo.
aCNS includes spinal cord, brain, and meninges.
bPrevious therapies include those used in the adjuvant setting or to treat advanced disease.
cOnly most frequently used clinically signiﬁcant medications in the elderly population. Percentages are based on the number of patients who received at least 1 dose of study treatment and who had at
least 1 valid postbaseline safety assessment.
dExcluding heparin.
Note: Data from December 15, 2011, safety update cut point.
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424 -metastases and sensitivity to previous hormone therapy. Treatment
continued until intolerable toxicity, withdrawal of consent, or dis-
ease progression.
Study End Points
The primary end point was PFS, deﬁned as the time from
randomization to the ﬁrst documentation of disease progression (as
assessed by the local investigator according to Response Evaluation
Criteria in Solid Tumors21 or, in the case of nonmeasurable [bone-
only] disease, unequivocal progression or appearance of new lesions)
or death from any cause. Analysis of PFS by central review was a
conﬁrmatory end point. For the elderly subset analyses, all efﬁcacy
data are based on local investigator assessments.
The key secondary end point was overall survival. Other sec-
ondary end points included objective response rate (deﬁned as
complete or partial response), clinical beneﬁt rate (complete
response, partial response, or stable disease for  24 weeks), time to
overall response and duration of overall response according to
Response Evaluation Criteria in Solid Tumors,21 change in quality-
of-life scores over time, time to deterioration of Eastern Cooperative
Oncology Group (ECOG) performance status, and safety.
Efﬁcacy and Safety Assessments
An independent data monitoring committee performed regular
safety reviews and reviewed the interim PFS and overall survivalClinical Breast Cancer December 2013results, and a steering committee supervised the conduct of the
study. Tumor evaluation based on computed tomography or mag-
netic resonance imaging was performed at baseline (within 6 weeks
before randomization) and every 6 weeks thereafter until disease
progression and initiation of further anticancer therapy. AEs were
assessed at each study visit and were graded according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0.22 Dose modiﬁcations (reductions,
interruptions, delays) and treatment discontinuations were also
evaluated. Dose interruptions were deﬁned as skipping a dose
for  1 day. Two dose reductions (from 10 mg/d to 5 mg/d; from
5 mg/d to 2.5 mg/d) were allowed by the protocol.
Statistical Analysis
The primary end point, PFS, was analyzed based on the data
from the full analysis set on an intent-to-treat basis. Kaplan-Meier
estimates were used to assess PFS in the elderly population; haz-
ard ratios and 95% conﬁdence intervals (CIs) were estimated using
an unstratiﬁed Cox regression method. Assessment of PFS in the
elderly subset was protocol-speciﬁed using 65 years of age as the
cutoff, whereas additional analyses using 70 years of age as the cutoff
were exploratory in nature. Time to deﬁnitive deterioration in
ECOG performance status was also assessed by the Kaplan-Meier
method. Deterioration in performance status was considered
deﬁnitive if no improvements were observed at a subsequent time of
Kathleen I. Pritchard et almeasurement during the treatment period after the time point at
which the deterioration was recorded. Death occurring within twice
the planned period between 2 assessments was considered as
worsening of the ECOG performance status.
Results
Patient and Treatment Characteristics
The overall study included 724 patients in the intent-to-treat
population and 720 patients in the safety population. At the time
of this analysis (cutoff date December 15, 2011), median follow-up
was 18 months on study, which corresponds to nearly 11 months
on study beyond the interim analysis reported by Baselga et al.16
Among 724 postmenopausal patients in BOLERO-2, there were
275 patients  65 years of age (195 receiving EVE þ EXE) and 164
patients  70 years of age (121 patients receiving EVE þ EXE)
(Table 1). Here we report the analyses for patients  65 years
(protocol-speciﬁed analyses) and patients  70 years of age (addi-
tional exploratory analyses). For clinical relevance, data obtained
from the  70-year-old patient population is primarily presented
throughout the text (unless otherwise speciﬁed, “elderly” refers to
patients  70 years of age), and corresponding data from the 65-
year-old cutoff can be found in the online Supplementary
Appendix (Tables S1-S6; Fig. S1).
Baseline disease characteristics and treatment histories among
the elderly subset were generally comparable with those of
younger patients. However, the baseline performance status for
elderly patients was slightly worse when compared with that of
younger patients; 3.3% and 9.3% of elderly patients treated with
EVE þ EXE and PBO þ EXE had a performance status of 2,
respectively, whereas 1.4% and 1.5% of younger patients treated
with EVE þ EXE and PBO þ EXE had a performance status of 2,
respectively (Table 1). The previous use of chemotherapy in the
adjuvant/neoadjuvant setting was less common in older patients
(Table 1). Notable differences were observed in the rates of speciﬁc
comorbidities at study entry between the elderly and younger
subsets and between treatment arms within the elderly subsetTable 2 Patient Disposition
Variable
Age < 70 years
EVE D EXE (n [ 364) PBO D EXE (
Randomized 100 100
Ongoing 18.4 4.1
Discontinued 81.6 95.9
Reason for discontinuation
Disease progression 67.0 88.8
Patient withdrew consent 6.3 2.0
Adverse events 6.3 4.1
Death 0.8 0.5
Protocol deviation 0.3 0
New cancer therapy 0.5 0.5
Administrative problems 0 0
Abbreviations: EVE ¼ everolimus; EXE ¼ exemestane; PBO ¼ placebo.
Note: Data from December 15, 2011, safety update cut point.(Table 1). Substantially higher rates of speciﬁc continuing medical
conditions—including respiratory system abnormalities, metabolic
and nutritional disorders, and vascular disorders—were present in
elderly patients in the EVE þ EXE arm compared with patients in
the PBO þ EXE arm or compared with younger patients in both
treatment arms. In general, the baseline comorbidity proﬁles in the
elderly vs. younger subsets reﬂected expected differences; however,
imbalance between treatment arms within the elderly subset might
have affected safety outcomes during the study. Similar trends were
observed using 65 years as the cutoff for elderly patients (Table S1).
Concomitant medications before the start of study treatments in the
elderly vs. younger subsets were largely consistent with their co-
morbidity proﬁles. The most commonly used medications in elderly
patients included all classes of antihypertensive agents, opioid
analgesics, nonheparin anticoagulants, statins, proton pump in-
hibitors, benzodiazepine derivatives, bisphosphonates, and thyroid
hormones. Usage rates for all these agents with the exception of
bisphosphonates were higher in the elderly subset when compared
with younger patients (Table 1). In addition, there were imbalances
between treatment arms in usage rates for some classes of medica-
tion within the elderly subset—thyroid hormones, anticoagulants,
statins, and bisphosphonates were more frequently used in the
PBO þ EXE arm than in the EVE þ EXE arm. In contrast,
benzodiazepine derivatives and proton pump inhibitors were more
frequently used in the EVE þ EXE arm than in the PBO þ EXE
arm. Overall, comorbidities and concomitant medication use before
the start of study treatments were as expected for elderly patients,
albeit not perfectly balanced between treatment arms.
At the time of data cutoff, more patients were continuing EVE þ
EXE treatment when compared with those receiving PBO þ EXE,
regardless of age. In the elderly subset, 11.6% of patients were
continuing EVE þ EXE treatment (vs. 4.7% of patients receiving
PBO þ EXE). In the younger subset, 18.4% of patients were
continuing EVE þ EXE treatment vs. 4.1% continuing PBO þ
EXE treatment (Table 2). For those patients who discontinued
study treatment, disease progression was the primary reason forPatients, %
Age ‡ 70 years
n [ 196) EVE D EXE (n [ 121) PBO D EXE (n [ 43)
100 100
11.6 4.7
88.4 95.3
46.3 88.4
19.0 7.0
17.4 0
3.3 0
1.7 0
0 0
0.8 0
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426 -discontinuation, regardless of treatment arm (Table 2). Withdrawal
of consent occurred more frequently in elderly patients than in
younger patients in the EVE þ EXE arm, as did permanent
discontinuation of study treatment because of AEs (Table 2).
For the elderly patients treated with EVE þ EXE, the mean
duration of exposure to EVE was 23.2 weeks and the mean duration
of exposure to EXE was 27.4 weeks. The mean duration of EVE
exposure was greater (33.8 weeks) in younger patients treated with
EVE þ EXE; however, the EVE dose intensity was generally similar
between these age groups. Speciﬁcally, the median dose intensity
of EVE was 7.2 mg/d (mean, 6.9 mg/d) in the elderly patients
and 8.9 mg/d (mean, 7.8 mg/d) in the younger patients (Table 3).
There was no signiﬁcant inﬂuence of age on the clearance of EVE
(data not shown). For younger patients treated with EVE þ EXE,
the mean duration of exposure to EXE was 36.1 weeks. For younger
patients treated with PBO þ EXE, the mean duration of exposure
to EXE was 21.8 weeks vs. 19.3 weeks for elderly patients treated
with PBO þ EXE (Table 3).
Efﬁcacy
At the time of this analysis, EVE þ EXE reduced the risk of PFS
events in all patients examined in BOLERO-2 (median PFS, 7.8
months vs. 3.2 months, respectively; hazard ratio, 0.45; 95% CI,
0.38-0.54; P < .0001), irrespective of age.15 In elderly patients
treated with EVE þ EXE, the risk of PFS events was reduced by
55% (hazard ratio, 0.45; 95% CI, 0.30-0.68) compared with
PBO þ EXE. In younger patients, EVE þ EXE resulted in a
relative risk reduction in PFS events of 56% compared with PBO þ
EXE (hazard ratio, 0.44; 95% CI: 0.36-0.54) (Fig. 1). The addition
of EVE to EXE increased the median PFS to 6.77 months from
1.51 months with PBO þ EXE in elderly patients. Median PFS was
also increased in the younger patients receiving EVE þ EXE
compared with those receiving PBO þ EXE (8.11 months vs. 4.01
months, respectively) (Fig. 1). Similarly, in patients  65 years of
age treated with EVE þ EXE, the risk of PFS events was reduced by
41% (hazard ratio, 0.59; 95% CI, 0.43-0.80) compared with
patients < 65 years of age (Supplementary Appendix Online,
Fig. S1). The combination of EVE þ EXE increased the median
PFS in patients  65 years of age compared with PBOþ EXE (6.83
months vs. 4.01 months, respectively) (Supplementary Appendix
Online, Fig. S1).
Patients treated with EVE þ EXE had a greater clinical beneﬁt
rate compared with patients treated with PBO þ EXE, including
patients in the elderly subsets. In elderly patients, the clinical beneﬁt
rate in the EVE þ EXE arm was 35.5% vs. 23.3% in the PBO þ
EXE arm. Similarly, patients treated with EVE þ EXE had a greater
objective response rate compared with patients treated with PBO þ
EXE, regardless of age group (Table 4). Progressive disease was more
common in patients of all ages who received PBO þ EXE as
opposed to EVE þ EXE (Table 4).
Safety
Dose modiﬁcations were similar between the elderly subsets and
the younger patients at data cutoff. For both the elderly and
younger patient subsets, 67% of patients receiving EVE þ EXE
required dose modiﬁcations, whereas 22% of younger patients and
16% of elderly patients who received PBO þ EXE required doseClinical Breast Cancer December 2013
Figure 1 Kaplan-Meier Analysis of Progression-Free Survival (PFS) in Patients With Advanced Breast Cancer who Were (A) < 70 Years
of age and (B) ‡ 70 Years of age
Abbreviations: CI ¼ conﬁdence interval; EVE ¼ everolimus; EXE ¼ exemestane; HR ¼ hazard ratio; PBO ¼ placebo.
Kathleen I. Pritchard et almodiﬁcations (Table 3). The primary reason for dose reductions or
interruptions was AEs, regardless of age. The proportion of patients
requiring at least 1 dose interruption in the elderly subset was
62.7% for EVE in the EVE þ EXE arm (57.6% for AEs) and
11.6% for PBO in the PBO þ EXE arm (7.0% for AEs). The
corresponding proportion in the younger subset was 60.7% for EVE
in the EVE þ EXE arm (55.2% for AEs) and 19.5% for PBO in the
PBO þ EXE arm (10.8% for AEs). The proportion of patients
requiring at least 1 dose reduction in the elderly subset was 39.0%
for EVE in the EVE þ EXE arm (38.1% for AEs) and 4.7% for
PBO in the PBO þ EXE arm (all for AEs). The corresponding
proportion in the younger subset was 39.6% for EVE in the EVE þ
EXE arm (37.4% for AEs) and 3.6% for PBO in the PBO þ EXE
arm (2.6% for AEs). Overall, 13.6% of elderly patients vs. 15.1% of
younger patients required more than 1 dose reduction for EVE in
the EVE þ EXE arm.
Across the overall study population, the most common
treatment-emergent AEs reported for EVE þ EXE were stomatitis,
rash, and fatigue.16 Among elderly patients, the most common AEs
were stomatitis (49% overall—24% grade 2, 8% grade 3), fatigue
(38% overall—17% grade 2, 9% grade 3, 2% grade 4), decreased
appetite (36% overall—14% grade 2, 3% grade 3), and diarrhea(36% overall—10% grade 2, 2% grade 3) (Table 5). There was a
lower incidence of stomatitis, rash, headache, nail disorders, hy-
percholesterolemia, and liver enzyme increases in the elderly subsets
receiving EVE þ EXE than in the younger subsets (Table 5). In
contrast, the incidence of decreased appetite, dyspnea, anemia,
asthenia, increased creatinine levels, and urinary tract infections
were higher in elderly patients receiving EVE þ EXE than in
the younger cohorts (Table 5). Time to deterioration in ECOG
performance status was similar between treatment arms in elderly
patients (Tables 6 and S6), suggesting that potential reductions in
performance status because of AEs may have been offset by pres-
ervation of performance status as a result of longer disease control in
the EVE þ EXE arm vs. that in the PBO þ EXE arm.
The most common grade 3/4 AEs ( 5%) across all age groups in
the EVE þ EXE treatment arm were stomatitis, fatigue, dyspnea,
anemia, increased gamma-glutamyltransferase levels, and hypergly-
cemia, which were similar regardless of patient age. With the
notable exception of stomatitis, rash, diarrhea, and headache, the
incidence of grade 3/4 AEs among patients who received EVE þ
EXE was somewhat higher in the elderly subsets than in the younger
patients (Table 5). The increased frequency of grade 3/4 dyspnea
was paralleled by an increased frequency of grade 3/4 cough ( 3%)Clinical Breast Cancer December 2013 - 427
Table 4 Best Tumor Response and Response Rate
Response
Patients, %
Age < 70 years Age ‡ 70 years
EVE D EXE (n [ 364) PBO D EXE (n [ 196) EVE D EXE (n [ 121) PBO D EXE (n [ 43)
Tumor Response
Complete 0.3 0 1.7 0
Partial 13.5 0.5 7.4 7.0
Stable disease 72.5 64.3 67.8 34.9
Progressive disease 9.6 29.6 11.6 46.5
Objective Response Ratea 13.7 0.5 9.1 7.0
Clinical Beneﬁt Rateb 56.6 27 35.5 23.3
Abbreviations: EVE ¼ everolimus; EXE ¼ exemestane; PBO ¼ placebo.
aComplete and partial responses.
bComplete and partial responses plus stable disease lasting  24 wk.
Note: Data from December 15, 2011, safety update cut point.
Safety of Exemestane ± Everolimus in the Elderly
428 -(Table 5). The incidence of grade 4 AEs was low (< 5%), regardless
of treatment arm or age subset. The mean weight loss from baseline
in the EVE þ EXE arm was slightly less for older vs. younger
patients (4.8 kg vs. 5.4 kg). Average weight loss compared with
baseline in the PBO þ EXE arm was similar across the age groups:
1.7 kg for both of the elderly cohorts and 1.8 kg for both of the
younger cohorts (data not shown).
A subset analysis of patients  75 years of age was also conducted
for safety, because this is a growing population in the HRþ breast
cancer setting, most likely because of the longer disease-free intervals
elicited from highly effective adjuvant AI therapy.23 The BOLERO-
2 trial included 71 patients in this age group who were treated with
EVE þ EXE and 22 patients treated with PBO þ EXE. As was the
case in patients with age cutoffs around 65 and 70 years, there were
very few grade 4 AEs reported for either treatment arm and none
with an incidence  5%. The most common AEs after EVE þ EXE
exposure were similar to those reported in the other elderly subsets
and included stomatitis (49%), fatigue (48%), decreased appetite
(41%), diarrhea (38%), nausea (38%), dyspnea (34%), rash (34%),
decreased weight (31%), and anemia (28%). The most common
grade 3/4 AEs ( 5%) in this subset of patients ( 75 years of age)
in the EVE þ EXE treatment arm were fatigue (14%, grade 3/4),
stomatitis (10%, grade 3), dyspnea (10%, grade 3), and anemia
(10%, grade 3/4) (data not shown).
At the time of this 18-month follow-up analysis, 200 deaths had
been reported (25.4% of patients in the EVE þ EXE arm vs. 32.2%
in the PBO þ EXE arm), the majority of which were attributable to
disease progression. Other causes of death included infections,
neoplasms, stroke, psychiatric disorders, tumor hemorrhage, and
renal failure. In the  70-year-old group, on-treatment deaths
resulting from AEs occurred in 4 patients who received EVE þ
EXE; these were attributed to renal failure, ischemic stroke, infec-
tion, and suicide (n ¼ 1 each). No deaths were reported for patients
who received PBO þ EXE in the  70-year-old group. In the
younger subset, there were 3 on-treatment deaths attributed to AEs
in the EVE þ EXE arm and 1 on-treatment death caused by AEs in
the PBO þ EXE arm (Table 6). After adjustment for treatment
exposure, the incidence of on-treatment deaths resulting from AEs
was similar between the EVE þ EXE and PBO þ EXE arms inClinical Breast Cancer December 2013patients < 70 years of age (1.3% each) but was higher in the EVE þ
EXE arm (7.7%) vs. the PBO þ EXE arm (0) in the  70-year-old
group. Careful monitoring and appropriate management (including
dose reduction/interruption when indicated) is recommended in
general during EVE þ EXE treatment but particularly in these
elderly patients.15
Discussion
Breast cancer can affect patients of nearly any age, with roughly
one quarter of all cases occurring in women < 50 years of age and
one ﬁfth of all cases occurring in women > 75 years of age.24
Advances in breast cancer detection and therapies have resulted in
a decline in both the risk of and death from breast cancer, especially
for younger patients. Elderly patients have not experienced as pro-
nounced a beneﬁt as younger patients for a number of reasons,
including lower frequency of screening, underrepresentation of
elderly cohorts in clinical trials, and increased toxicity from
chemotherapeutic agents (thereby limiting the feasibility of
achieving maximally effective doses and/or durations of therapy). In
addition, concerns about the tolerability of treatments result in the
use of less aggressive therapy in elderly patients.24 Variations in the
deﬁnition of “elderly” populations may complicate comparisons
with completed breast cancer studies that include elderly cohorts.
National and international breast cancer clinical trials have used
either 65 or 70 years as the age limit for eligibility.25 Because the
life expectancy at 70 years may be > 15 years in healthy women
and < 9 years in women with comorbidities in addition to breast
cancer, it is also important to determine safety signals of breast
cancer therapies in women of advanced age ( 75 years).25 The
BOLERO-2 trial had no age restrictions for eligibility (other than
being  18 years of age); therefore, multiple age cutoffs for analysis
of the efﬁcacy and safety proﬁle of EVE are presented herein.
Results from the phase III BOLERO-2 study revealed that a
dual-blockade strategy (ie, concomitantly inhibiting endocrine
signaling and pathways involved in cross talk with the ER [eg,
PI3K/mTOR]) may help improve outcomes in patients with HRþ
disease that progresses on NSAIs. Indeed, the addition of EVE
to EXE more than doubled PFS while maintaining quality of life in
the overall study population.16 Of the 724 patients in this study,
Table 5 Any Grade Treatment-Emergent Adverse Events With ‡ 10% Incidence in the EVE D EXE Groups (Regardless of Cause)
Adverse Event
Patients, %
Age < 70 years Age ‡ 70 years
EVE D EXE PBO D EXE EVE D EXE PBO D EXE
Grade Any 3/4 Any 3/4 Any 3/4 Any 3/4
Stomatitis 62 8 13 1 49 8 5 0
Rash 42 1 7 0 31 2 7 0
Fatigue 37 3 28 2 38 10 23 0
Diarrhea 34 3 19 1 36 2 19 0
Nausea 30 0.3 29 2 33 2 28 0
Appetite decrease 29 1 11 0.5 36 3 23 2
Weight decrease 27 1 7 0 29 3 7 0
Headache 26 0.5 15 0 11 0 12 0
Cough 25 0.3 12 0 26 3 9 0
Dysgeusia 23 0 7 0 20 0 2 0
Arthralgia 21 0.3 17 0.5 19 3 14 0
Peripheral edema 21 1 5 0.5 20 1 14 0
Dyspnea 20 4 10 2 28 8 16 0
Vomiting 18 1 13 1 17 0.8 14 0
Anemia 17 7 6 1 31 10 2 0
AST increase 16 4 7 2 7 2 0 0
Pyrexia 17 0.3 7 0.5 14 0 5 0
Pneumonitis 17 3 0 0 14 5 0 0
ALT increase 15 4 6 3 4 3 0 0
Back pain 15 0 10 2 14 0.8 14 0
Pruritus 14 0 5 0 12 0.8 5 0
Hyperglycemia 15 5 3 0.5 12 8 0 0
Epistaxis 18 0 1 0 14 0 2 0
Constipation 15 0.3 13 0.5 13 2 16 0
Insomnia 15 0.3 8 0 12 0 9 0
Hypercholesterolemia 11 0.3 1 0 7 0.8 0 0
Nasopharyngitis 12 0 10 0 6 0 2 0
Thrombocytopenia 12 2 0.5 0 15 3 0 0
GGT increase 11 6 10 8 8 7 2 2
Asthenia 12 2 3 0 20 3 12 2
Nail disorder 10 0 0.5 0 3 0 0 0
Dry mouth 10 0 6 0 14 0 14 0
Alopecia 10 0 5 0 12 0 5 0
Creatinine increase 6 1 1 0 15 0.8 0 0
Urinary tract infection 9 0.5 2 0 15 0 5 0
Abbreviations: ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; EVE ¼ everolimus; EXE ¼ exemestane; GGT ¼ gamma-glutamyltransferase; PBO ¼ placebo.
Note: Data from December 15, 2011, safety update cut point.
Kathleen I. Pritchard et al275 (38.0%) were  65 years of age and 164 (22.7%) were  70
years of age, providing an opportunity to determine the efﬁcacy and
safety of EVE in combination with EXE in these underserved
elderly subsets. Moreover, the 2:1 randomization of EVE þ EXE vs.
PBO þ EXE afforded an increased opportunity to determine the
safety proﬁle of EVE in this elderly population of patients.
Elderly women have an increased vulnerability to breast cancer
but are also at higher risk for a host of other health problems than
are younger women.26 At diagnosis of breast cancer, post-
menopausal women often have at least 1 preexisting comorbidity,
such as heart disease, diabetes, osteoporosis, or chronic obstructivepulmonary disease.26 The total number of comorbidities increases
with age, as does the percentage of patients with more severe
comorbidities (and associated mortality).26 One retrospective study
found that unlike younger patients with cancer, breast cancer in
elderly women was causatively linked to a smaller proportion of
deaths than were cardiovascular and cerebrovascular diseases.26
Although HRþ breast cancer is considered to be generally asso-
ciated with lower mortality (as a proportion of overall incidence)
than the HR-negative (HR) subtype, treatment options after initial
endocrine therapies offer limited clinical beneﬁt.5 Development of
new approaches for the treatment of advanced breast cancer mayClinical Breast Cancer December 2013 - 429
Table 6 Performance Status, Deaths by Primary System Organ Class, and Annualized Incidence Rate of On-Treatment Deaths From AEs
Variable
Age < 70 years Age ‡ 70 years
EVE D EXE
(n [ 364)
PBO D EXE
(n [ 195)
EVE D EXE
(n [ 118)
PBO D EXE
(n [ 43)
ECOG Performance Status, %a,b
0 61.8 61.2 56.2 51.2
1 34.9 34.2 38.8 39.5
2 1.4 1.5 3.3 9.3
Unknown 1.9 3.1 1.7 0
Kaplan-Meier Estimates of Time to Deﬁnitive
Deterioration in ECOG Performance Status, mob
Number of Events, n (%) 107 (29.4) 51 (26.0) 58 (47.9) 16 (37.2)
Deﬁnitive deterioration 104 (28.6) 47 (24.0) 55 (45.5) 15 (34.9)
Number Censored, n (%) 257 (70.6) 145 (74.0) 63 (52.1) 27 (62.8)
25th Percentile (95% CI) 6.9 (4.6, 8.4) 5.6 (4.2, 7.2) 2.6 (1.5, 4.0) 2.5 (1.5, 6.0)
Median (95% CI) NA (17.5, NA) 9.7 (8.3, NA) 9.8 (4.7, 12.9) 9.2 (4.2, NA)
75th percentile (95% CI) NA 18.89 (18.9, NA) 22.14 (12.9, NA) 13.77 (9.2, NA)
Deaths, %c 2.2 1.5 9.3 2.3
Reason for Death, n (%)
Disease progression 5 (1.4) 2 (1.0) 7 (5.9) 1 (2.3)
Infections and infestations 2 (0.5)d,e 1 (0.5)d 1 (0.8)e 0
Neoplasms (tumor hemorrhage) 1 (0.3) 0 0 0
Nervous system disorders 0 0 1 (0.8)f 0
Psychiatric disorders (suicide) 0 0 1 (0.8) 0
Renal disorders (failure) 0 0 1 (0.8) 0
Total Patient Years Exposed, n 236 79 52 16
On-Treatment Deaths With AEs As Primary
Cause, n (Exposure Adjusted %)
3 (1.3) 1 (1.3) 4 (7.7) 0
Abbreviations: AE ¼ adverse event; CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative Oncology Group; EVE ¼ everolimus; EXE ¼ exemestane; NA ¼ not assessable; PBO ¼ placebo.
aPerformance status at baseline.
bFor ECOG performance status, percentages are based on the number of patients randomized: 364 for EVE þ EXE and 196 for PBO þ EXE in the younger subset and 121 for EVE þ EXE and 43 for
PBO þ EXE in the elderly subset.
cDeaths occurring > 28 days after discontinuation of study treatment are not summarized.
dPneumonia.
eSepsis and/or staphylococcal sepsis.
fIschemic stroke.
Note: Data from December 15, 2011, safety update cut point.
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430 -help prolong the time that endocrine therapy is effective, a
consideration especially pertinent to elderly patients who generally
experience higher levels of AEs (eg, myelosuppression, cardiac
dysfunction, mucositis, and central neurotoxicity) with cytotoxic
chemotherapy and often present with comorbidities and compro-
mised physical and biological function in comparison with younger
patients.6,27 Interestingly, it has been reported that a phenotype of
HRþ breast cancer associated with lower mortality is more common
in elderly patients than in younger patients, yet elderly patients are
often excluded from aggressive and/or investigative treatment op-
tions.24,26 Indeed, the typical eligibility criteria pertaining to general
health, performance status, and adequate metabolic function in
clinical trials have resulted in underrepresentation of elderly patients
(especially those > 80 years) and of patients with impaired per-
formance status. As with most clinical trials in advanced breast
cancer, BOLERO-2 required participants to have a performance
status of 2 or better and to have adequate bone marrow, renal, and
hepatic function—criteria that may have excluded very elderlyClinical Breast Cancer December 2013patients with multiple comorbidities and/or myelosuppression from
previous chemotherapy.
In BOLERO-2, the EVE þ EXE combination clearly demon-
strated substantial efﬁcacy and consistent tolerability in the elderly
subsets of patients with HRþ advanced breast cancer compared with
PBO þ EXE treatment. In elderly patients, the addition of EVE to
EXE signiﬁcantly improved the median PFS by 2.82 months in
patients  65 years of age (hazard ratio, 0.59) and by 5.26 months in
patients 70 years of age (hazard ratio, 0.45) compared with PBOþ
EXE, without eliciting any new safety concerns. Overall, EVEþ EXE
treatment was generally well tolerated, and EVE þ EXEerelated
grade 3/4 AEs were uncommon, manageable, and consistent with
those previously reported for rapamycin analogues in other malig-
nancies.28,29 Treatment with EVE þ EXE was associated with a low
incidence of myelosuppression, which is typically a dose-limiting
toxicity with chemotherapy in elderly patients.6 Notably, the
EVE þ EXE combination was associated with reduced levels of bone
turnover markers as well as reduced rates of disease progression in
Kathleen I. Pritchard et albone compared with PBO þ EXE,30 suggesting a potential bone-
sparing effect of EVE, which might be especially beneﬁcial in
elderly women who are already at risk for age-related osteoporosis.
The safety proﬁle of EVE in combination with EXE in this
analysis of elderly patients in BOLERO-2 was similar to that re-
ported for the elderly subset of patients (n ¼ 153) in RECORD-1
(REnal Cell cancer treatment with Oral RAD001 given Daily), a
phase III trial evaluating the efﬁcacy and safety of EVE vs. PBO in
metastatic renal cell carcinoma.31,32 As in BOLERO-2, most AEs in
RECORD-1 were grade 1 or 2 in severity, regardless of age; grade
3/4 AEs were uncommon in both the elderly and the overall
RECORD-1 and BOLERO-2 populations, supporting the overall
tolerability of EVE regardless of age.31,32 In the RECORD-1 trial,
elderly patients ( 70 years of age) experienced an increased fre-
quency of AEs that resulted in EVE dose reductions and an
increased occurrence of > 1 dose interruption/reduction when
compared with patients  65 years of age and with the overall study
population.32 In the BOLERO-2 trial, elderly patients experienced
similar rates of EVE dose reduction/interruption as did the younger
patients; however, more elderly patients discontinued EVE þ EXE
treatment because of AEs when compared with younger patients.
Diligent monitoring and implementation of appropriate EVE dose
modiﬁcations for AEs are recommended for elderly patients.
Decreased weight has been reported as a common AE for EVE.15
Slightly more than 25% of EVE þ EXE patients in this study
experienced decreased weight (all grades), and this frequency was
consistent across all age subsets. This is a notable side effect because
many patients with breast cancer gain weight after therapy.33
Weight loss after EVE þ EXE treatment may be attributed in
part to concomitant stomatitis, decreased appetite, and nausea,
which are also commonly reported AEs for EVE.15 The careful and
proactive management of stomatitis and anorexia may help to avoid
signiﬁcant weight loss during EVE therapy.
Consistent with the overall efﬁcacy of EVE þ EXE in BOLERO-
2, fewer patients in the EVE þ EXE arm died compared with those
in the PBO þ EXE arm, and disease progression was the leading
cause of death overall. Although on-treatment deaths caused by AEs
occurred more frequently in patients receiving EVE þ EXE than in
those receiving PBO þ EXE, it is plausible that the risk of on-
treatment death is related to the duration of therapy. As patients
in BOLERO-2 were exposed to EVE þ EXE for a longer duration
compared with those receiving PBO þ EXE, regardless of age, it is
possible that the higher rate of on-treatment deaths on EVE þ EXE
may be attributable in part to the longer period at risk. The higher
incidence of on-treatment deaths caused by AEs in the elderly
subsets compared with younger patients may also reﬂect differences
in overall health status (eg, performance status) at study entry.
Pneumonia was a cause of on-treatment death in elderly and
younger patients, regardless of treatment. The combination of
EVE þ EXE resulted in additional deaths from tumor hemorrhage
in the younger patient cohorts only and from ischemic stroke, renal
failure, suicide, and sepsis in the elderly patient cohorts only.
Notably, elderly patients ( 70 years of age) in the EVE þ EXE
arm had increased baseline prevalence (vs. those in the
PBO þ EXE arm) of vascular disorders (12% vs. 7%—including
hypertension and deep vein thrombosis), cerebrovascular accidents
(2.5% vs. 0%), anemia (4% vs. 0%), psychiatric disorders(6% vs. 0%—including anxiety, depression, and panic attacks),
and infections and infestations (17% vs. 12%). Moreover, there
were more obese patients (deﬁned as body mass index  30) at
baseline among elderly patients treated with EVE þ EXE
compared with those treated with PBO þ EXE (26% vs. 14%).
Careful consideration of the likelihood for a particular AE to
develop in elderly patients, especially in the context of preexisting
comorbidities, is strongly recommended before treatment.
In summary, the addition of EVE to EXE provided substantial
clinical beneﬁt to both elderly and nonelderly patients and repre-
sents an important improvement in the management of post-
menopausal women, regardless of age, who have HRþ HER2
advanced breast cancer that progresses after NSAI treatment.
Optimizing the beneﬁt of this combination in elderly patients
should include appropriate patient selection and proactive man-
agement of AE risk in the context of comorbidities common in the
elderly population. In addition, careful monitoring for AEs is
needed during treatment to facilitate early diagnosis and appropriate
management (including dose reduction or interruption when
appropriate).
Clinical Practice Points
 The BOLERO-2 trial showed that the combination of EVE þ
EXE provides clinically meaningful beneﬁt to postmenopausal
women with HRþ advanced breast cancer and, additionally, may
help delay the need for chemotherapy.
 The efﬁcacy and tolerability of this combination in elderly pa-
tients are especially relevant in view of the typical age distribution
of women with HRþ advanced breast cancer.
 Understanding and managing the AE proﬁle of EVE through
patient and health care provider education and regular moni-
toring are key to maximizing the potential beneﬁts from the
EVE þ EXE combination regimen. Careful monitoring and
proactive management of AEs are recommended for elderly
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Figure 1S Kaplan-Meier Analyses of Progression-Free Survival in Patients With Advanced Breast Cancer who Were (A) < 65 Years of
age; (B) ‡ 65 Years of age
Abbreviations: CI ¼ conﬁdence interval; EVE ¼ everolimus; EXE ¼ exemestane; HR ¼ hazard ratio; PBO ¼ placebo; PFS ¼ progression-free survival.
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Table 1S Patient Demographic, Baseline Disease, and Treatment Characteristics
Patients, %
Age < 65 years Age ‡ 65 years
EVE D EXE
(n [ 290)
PBO D EXE
(n [ 159)
EVE D EXE
(n [ 195)
PBO D EXE
(n [ 80)
Race
White 69.0 73.0 82.6 87.5
Asian 26.2 23.3 11.3 10.0
Black 2.4 0.6 3.1 2.5
Paciﬁc Islander 0.3 0.6 0.5 0
Other 2.1 2.5 2.6 0
ECOG performance status
0 64.8 59.1 53.8 60.0
1 31.4 37.1 42.6 31.3
2 1.4 1.3 2.6 6.3
Unknown 2.4 2.5 1.0 2.5
Number of metastatic sites
1 33.4 30.8 29.7 18.8
2 30.3 35.2 30.8 35.0
3 19.7 20.1 23.1 25.0
4 11.0 9.4 9.7 18.8
5 4.1 3.1 4.6 1.3
> 5 1.0 1.3 1.5 1.3
Metastatic site
CNSa 1.4 0 1.0 0
Visceral 55.2 56.0 63.1 66.3
Lung 28.3 28.3 31.3 42.5
Liver 32.8 30.2 34.4 31.3
Lung and liver 8.6 9.4 9.7 13.8
Bone 80.3 77.4 70.8 77.5
Bone only 25.9 23.9 15.4 10.0
Other 49.0 52.2 52.8 67.5
Previous chemotherapy
Adjuvant/neoadjuvant only 50.3 44.0 33.8 31.3
Metastatic only 13.1 10.1 14.9 8.8
Both adjuvant/neoadjuvant and
metastatic
16.6 18.9 5.1 10.0
Previous NSAI treatment 100 100 100 100
Tamoxifen 53.8 52.8 37.9 43.8
Fulvestrant 14.8 12.6 19.0 23.8
Purpose of NSAI treatment
Adjuvant/neoadjuvant 30.0 22.0 28.7 27.5
Metastatic disease 65.2 71.7 67.7 67.5
Both adjuvant/neoadjuvant and
metastatic
4.8 6.3 3.6 5.0
Sensitive to hormonal therapy 80.7 83.0 89.7 86.3
Number of prior therapiesb
1 10.0 13.8 23.6 26.3
2 27.2 27.7 34.9 32.5
3 28.6 22.6 25.1 25.0
 4 34.1 35.8 16.4 16.3
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Table 1S Continued
Patients, %
Age < 65 years Age ‡ 65 years
EVE D EXE
(n [ 290)
PBO D EXE
(n [ 159)
EVE D EXE
(n [ 195)
PBO D EXE
(n [ 80)
Key baseline comorbidities, %
Overall 67.9 68.6 74.9 78.8
Infections and infestations 11.7 13.2 17.4 11.3
Respiratory system abnormalities 8.3 8.8 10.8 6.3
Vascular disorders 6.9 7.6 10.3 7.5
Metabolic and nutritional disorders 1.7 2.5 6.2 5.0
Abbreviations: CNS ¼ central nervous system; ECOG ¼ Eastern Cooperative Oncology Group; EVE ¼ everolimus; EXE ¼ exemestane; NSAI ¼ nonsteroidal aromatase inhibitor; PBO ¼ placebo.
aCNS includes spinal cord, brain and meninges.
bPrior therapies include those used in the adjuvant setting or to treat advanced disease.
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Table 2S Patient Disposition
Patients, %
Age < 65 years Age ‡ 65 years
EVE D EXE (n [ 290) PBO D EXE (n [ 159) EVE D EXE (n [ 195) PBO D EXE (n [ 80)
Randomized 100 100 100 100
Ongoing 19.3 3.8 12.8 5.0
Discontinued 80.7 96.2 87.2 95.0
Reason for discontinuation
Disease progression 68.6 89.9 51.8 86.3
Patient withdrew consent 6.6 1.3 13.8 6.3
Adverse event(s) 4.5 3.8 15.9 2.5
Death 0.7 0.6 2.6 0
Protocol deviation 0.3 0 1.0 0
New cancer therapy 0 0.6 1.0 0
Administrative problems 0 0 0.5 0
Abbreviations: EVE ¼ everolimus; EXE ¼ exemestane; PBO ¼ placebo.
Note: Data from December 15, 2011, safety update cutpoint.
Safety of Exemestane ± Everolimus in the Elderly
432.e4 - Clinical Breast Cancer December 2013
Table 3S Treatment Characteristics
Age < 65 years Age ‡ 65 years
EVE D EXE (n [ 290) PBO D EXE (n [ 158) EVE D EXE (n [ 192) PBO D EXE (n [ 80)
EVE EXE PBO EXE EVE EXE PBO EXE
Mean total dose, mg (SD) 1986.19 (1466.93) 6328.62 (4217.05) 1347.47 (1187.20) 3534.49 (3008.80) 1464.97 (1396.89) 5219.27 (4447.41) 1608.50 (1459.42) 4090.63 (3659.70)
Mean duration of exposure, wk (SD) 34.0 (24.4) 36.4 (24.2) 19.6 (17.1) 20.3 (17.3) 26.9 (25.7) 30.3 (25.4) 23.3 (21.0) 23.5 (21.1)
Range, wk 1.4-109.4 3.3-109.4 1.0-77.1 1.0-77.1 1.0-123.3 1.0-123.3 2.0-101.0 2.0-101.0
Median dose intensity, mg/d 9.1 25.0 10.0 25.0 7.4 25.0 10.0 25.0
Mean dose intensity, mg/d (SD) 7.9 (2.5) 24.8 (0.8) 9.6 (1.4) 24.9 (0.5) 7.1 (2.7) 24.3 (2.1) 9.7 (0.8) 24.8 (1.3)
Dose reduction/interruption, n (%) 194 (66.9) 61 (21.0) 31 (19.6) 17 (10.8) 128 (66.7) 54 (28.1) 18 (22.5) 11 (13.8)
Abbreviations: EVE ¼ everolimus; EXE ¼ exemestane; PBO ¼ placebo; SD ¼ standard deviation.
Note: Data from December 15, 2011, safety update cutpoint. K
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Table 4S Best Tumor Response and Response Rate
Patient Disposition
Patients, %
Age < 65 years Age ‡ 65 years
EVE D EXE (n [ 290) PBO D EXE (n [ 159) EVE D EXE (n [ 195) PBO D EXE (n [ 80)
Tumor response
Complete 0.3 0 1.0 0
Partial 14.5 0 8.2 5.0
Stable disease 71.0 62.9 71.8 51.3
Progressive disease 9.7 30.8 10.8 36.3
ORRa 14.8 0 9.2 5.0
CBRb 58.3 23.9 41.0 31.3
Abbreviations: CBR ¼ clinical beneﬁt rate (complete or partial response or stable disease); EVE ¼ everolimus; EXE ¼ exemestane; ORR ¼ objective response rate (complete or partial response);
PBO ¼ placebo.
aComplete and partial responses.
bComplete and partial responses plus stable disease lasting  24 weeks.
Note: Data from December 15, 2011, safety update cutpoint.
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Table 5S Any-Grade Treatment-Emergent Adverse Events With ‡ 10% Incidence in the EVE D EXE Groups (Regardless of
Causality)
Patients, %
Age < 65 years Age ‡ 65 years
EVE D EXE PBO D EXE EVE D EXE PBO D EXE
Grade Any 3/4 Any 3/4 Any 3/4 Any 3/4
Stomatitis 63 7 14 1 53 9 8 0
Rash 44 1 6 0 32 2 8 0
Fatigue 37 3 29 1 37 7 25 1
Diarrhea 34 3 19 0.6 34 2 18 1
Nausea 29 0.3 32 2 33 1 23 0
Appetite decrease 28 0.7 10 0 35 3 19 3
Weight decrease 28 1 7 0 28 2 8 0
Headache 27 0.7 17 0 16 0 10 0
Cough 25 0.3 12 0 26 2 11 0
Dysgeusia 24 0 6 0 19 0 6 0
Arthralgia 23 0.3 18 0.6 17 2 14 0
Peripheral edema 21 1 4 0.6 20 0.5 10 0
Dyspnea 18 3 10 2 27 8 13 0
Vomiting 18 1 15 1 17 1 11 0
Anemia 18 6 7 1 26 9 1 0
AST increase 18 4 6 2 7 2 4 0
Pyrexia 17 0.3 8 0.6 15 0 4 0
Pneumonitis 17 2 0 0 15 5 0 0
ALT increase 16 4 4 2 6 2 6 3
Back pain 16 0 8 3 15 0.5 15 0
Pruritus 15 0 4 0 12 0.5 6 0
Hyperglycemia 15 5 3 0.6 13 7 0 0
Epistaxis 15 0 1 0 20 0 1 0
Constipation 13 0 11 0 17 2 18 1
Insomnia 13 0 10 0 15 0.5 6 0
Hypercholesterolemia 13 0.3 1 0 6 0.5 0 0
Nasopharyngitis 12 0 11 0 8 0 5 0
Thrombocytopenia 12 3 0.6 0.6 14 2 0 0
GGT increase 11 6 10 9 8 7 5 1
Asthenia 11 1 3 0 19 3 6 1
Nail disorder 11 0 0.6 0 4 0 0 0
Dry mouth 10 0 6 0 13 0 9 0
Alopecia 10 0 5 0 12 0 5 0
Creatinine increase 4 0.3 0.6 0 14 3 1 0
Urinary tract infection 8 0.7 0.6 0 13 0 5 0
Abbreviations: ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; EVE ¼ everolimus; EXE ¼ exemestane; GGT ¼ gamma-glutamyltransferase; PBO ¼ placebo.
Note: Data from December 15, 2011, safety update cutpoint.
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Table 6S Performance Status, Deaths by Primary System Organ Class, and Annualized Incidence Rate of On-treatment Deaths Due
to AEs
Age < 65 years Age ‡ 65 years
EVE D EXE
(n [ 290)
PBO D EXE
(n [ 158)
EVE D EXE
(n [ 192)
PBO D EXE
(n [ 80)
ECOG performance status, %a,b
0 64.8 59.1 53.8 60.0
1 31.4 37.1 42.6 31.3
2 1.4 1.3 2.6 6.3
Unknown 2.4 2.5 1.0 2.5
Kaplan-Meier estimates of time to deﬁnitive
deterioration in ECOG performance status, mob
Number of events, n (%) 83 (28.6) 42 (26.4) 82 (42.1) 25 (31.3)
Deﬁnitive deterioration 81 (27.9) 38 (23.9) 78 (40.0) 24 (30.0)
Number censored, n (%) 207 (71.4) 117 (73.6) 113 (57.9) 55 (68.8)
25th percentile (95% CI) 7.1 (4.7, 9.4) 5.0 (4.1, 6.9) 3.1 (2.3, 4.2) 4.2 (1.5, 8.4)
Median (95% CI) NA (18.1, NA) 8.8 (7.1, NA) 11.1 (7.9, 17.5) 13.8 (7.2, NA)
75th percentile (95% CI) NA NA (12.5, NA) NA (17.5, NA) 18.89 (13.8, NA)
Deaths, %c 2.1 1.9 6.8 1.3
Reason for death, n (%)
Disease progression 4 (1.4) 2 (1.3) 8 (4.2) 1 (1.3)
Infections and infestations 1 (0.3)d 1 (0.6)d 2 (1.0)d,e 0
Neoplasms (tumor hemorrhage) 1 (0.3) 0 0 0
Nervous system disorders 0 0 1 (0.5)f 0
Psychiatric disorders (suicide) 0 0 1 (0.5) 0
Renal disorders (failure) 0 0 1 (0.5) 0
Total patient years exposed, n 189 59 99 36
On-treatment deaths with AE as primary
cause, n (exposure adjusted %)
2 (1.1) 1 (1.7) 5 (5.1) 0
Abbreviations: AE, adverse event; CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology Group; EVE, everolimus; EXE, exemestane; NA, not assessable; PBO, placebo.
aPerformance status at baseline.
bFor ECOG PS, percentages are based on the number of patients randomized: 290 for EVE þ EXE and 159 for PBO þ EXE in the younger subset and 195 for EVE þ EXE and 80 for PBO þ EXE in the
elderly subset.
cDeaths occurring > 28 days after discontinuation of study treatment are not summarized.
dPneumonia.
eSepsis and/or staphylococcal sepsis.
fIschemic stroke.
Note: Data from December 15, 2011, safety update cutpoint.
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